#46
|
||||
|
||||
Îáíîâëåííûå ðåêîìåíäàöèè American Academy of Pediatrics ïî âåäåíèþ äåòåé ñ ñèíäðîìîì Äàóíà îò ðîæäåíèÿ äî 21 ãîäà
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#47
|
||||
|
||||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Î÷åíü ïîëåçíàÿ ññûëêà äëÿ ðîäèòåëåé ïðî àâòîáåçîïàñíîñòü äåòåé. |
#49
|
||||
|
||||
Review Article
Febrile Urinary Tract Infections in Children Giovanni Montini, M.D., Kjell Tullus, M.D., Ph.D., and Ian Hewitt, M.B., B.S. N Engl J Med 2011; 365:239-250July 21, 2011 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Öèòàòà:
Öèòàòà:
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |
#50
|
||||
|
||||
Äàâíî ÿ ñ ïåäèàòðàìè ññûëêàìè íå äåëèëàñü
 European Respiratory Journal îïóáëèêîâàíû ðåçóëüòàòû [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ], â êîòîðîå áûëè âêëþ÷åíû 5368 äåòåé. Öåëüþ èññëåäîâàíèå áûëî óñòàíîâëåíèÿ âçàèìîñâÿçè ìåæäó ïðîäîëæèòåëüíîñòüþ ãðóäíîãî âñêàðìëèâàíèÿ è ÷àñòîòîé ðàçâèòèÿ áðîíõèàëüíîé àñòìû ó äåòåé â â ïåðâûå 4 ãîäà æèçíè. Öèòàòà:
|
#51
|
||||
|
||||
JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print
DOI: 10.1097/MPG.0b013e3182227e90 Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#53
|
||||
|
||||
Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 11, 2011
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Licensure of a Meningococcal Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated Booster Dose Guidance for Adolescents and Other Persons at Increased Risk for Meningococcal Disease --- Advisory Committee on Immunization Practices (ACIP), 2011 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#54
|
||||
|
||||
A Look Back at the Effect of Varicella Vaccination on Varicella Deaths
In just over a decade, the average annual mortality rate for varicella-related deaths in the U.S. has declined 88%. During the first 6 years after the 1995 licensure of the varicella vaccine, varicella-related mortality in the U.S. dropped 66% (from 105 annual deaths to 39 deaths). This study examined varicella mortality from 2002 through 2007 — a period when vaccine coverage increased to about 90% of children aged 19 to 35 months. In 2002, varicella was listed in 32 records as the underlying cause of death. The annual number of varicella deaths in 2003 through 2007 ranged from 13 to 19; this represents an 88% decline in the average mortality rate from 0.41 per million in the immediate prevaccine years (1990–1994) to 0.05 per million in 2005–2007. The decline was greatest in patients younger than 20 (97%) but was also apparent in older patients (age, 20–49: 90%; age, >50: 67%). Only 11% of patients whose deaths were related to varicella had preexisting high-risk medical conditions (all were malignancies). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Near Elimination of Varicella Deaths in the US After Implementation of the Vaccination Program. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |
#55
|
||||
|
||||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
A New Approach to Managing Young Non–Toxic-Appearing Febrile Children Researchers suggest an emphasis on more-limited evaluation, now that vaccines have greatly reduced the likelihood of serious bacterial infections. Since the 1970s, considerable attention has been paid to the management of febrile children aged 3 years without an obvious focus of infection. Recommendations have emphasized detection of serious bacterial infections (SBIs), including occult bacteremia (OB), and empirical antibiotic treatment for children considered to be at high risk. Management has been determined using a combination of clinical appearance, age, and laboratory tests, with more testing recommended for infants aged <3 months than for those aged 3 to 36 months. Effective vaccines against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae, the two major causes of occult SBIs, have been universally available in the U.S. since 1988 and 2000, respectively. The incidence of invasive Hib infection in children aged <5 years dropped by 99% between 1987 and 2007, and the incidence of pneumococcal OB is currently <0.5%. Urinary tract infections (UTIs) are now the most common SBI in febrile children without localizing signs. Considering these changes, researchers from four major pediatric departments suggest that recommendations for managing such children be updated. These researchers state that new guidelines should emphasize the importance of immediate antimicrobial therapy for an infant who is seriously ill or toxic appearing and a complete clinical and laboratory evaluation for high-risk febrile infants aged 30 days, as we have been doing. However, for intermediate-risk infants aged 31 to 90 days, acceptable management can range from complete evaluation to simply observation and follow-up. And for infants aged 3 to 36 months who have received 2 doses of both Hib and pneumococcal conjugate vaccines, evaluation only for UTI is warranted. Comment: Although these recommendations don't carry the stamp of any official organization, they are supported by evidence. If they are put into practice, venipunctures, lab tests, cultures, and hospitalizations would all be reduced. — Robert S. Baltimore, MD
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |
#56
|
||||
|
||||
Ðåêîìåíäàöèè ÀÀÐ ïî îáåñïå÷åíèþ áåçîïàñíîñòè ïðè çàíÿòèÿõ ñïîðòîì â æàðêóþ ïîãîäó
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Îñíîâíûå ïîëîæåíèÿ Öèòàòà:
|
#57
|
||||
|
||||
Few Adverse Events Linked to Vaccines
Institute of Medicine îïóáëèêîâàë [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ], èçó÷àâøåé ÷àñòîòó ðàçâèòèÿ ïîáî÷íûõ ýôôåêòîâ ïîñëå ïðèìåíåíèÿ 8 íàèáîëåå ðàñïðîñòðàíåííûõ âàêöèí (ïðîòèâ êîðè, êðàñíóõè, ïàðîòèòà (MMR), ñòîëáíÿêà, ìåíèíãîêîêêîâîé èíôåêöèè, âåòðÿíîé îñïû, ÂÏ×, ãåïàòèòîâ À è Â, ãðèïïà (íå H1N1)).  ïîäàâëÿþùåì áîëüøèíñòâå ñëó÷àåâ íå óäàëîñü ïîëó÷èòü óáåäèòåëüíûõ äîêàçàòåëüñòâ ñâÿçè ðàçâèòèÿ ðàçíîãî ðîäà ïîáî÷íûõ ýôôåêòîâ ñ ïðèìåíåíèåì âàêöèíû. Îïðîâåðãíóòà è òåîðèÿ Ýíäðþ Óýéêôèëäà (Andrew Wakefield) î âçàèìîñâÿçè ìåæäó âàêöèíàöèåé MMR-âàêöèíîé è àóòèçìîì.
Îñíîâíûå âûâîäû êîìèññèè Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#58
|
||||
|
||||
Îáíîâëåííûå ðåêîìåíäàöèè ÀÀÐ ïî ëå÷åíèþ ÈÌÏ ó äåòåé â âîçðàñòå 2-24 ìåñÿöåâ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Îñíîâíûå ïîëîæåíèÿ ãàéäëàéíà Öèòàòà:
|
#59
|
||||
|
||||
Ãàéä ïî äèàãíîñòèêå è ëå÷åíèþ âíåáîëüíè÷íîé ïíåâìîíèè ó äåòåé ñòàðøå 3 ìåñÿöåâ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Äàíû ðåêîìåíäàöèè ïî äèàãíîñòèêå è ñòàðòîâîé ÀÁ-òåðàïèè, îïðåäåëåíû ïîêàçàíèÿ ê ãîñïèòàëèçàöèè. Ðàññìîòðåí âîïðîñ î íåîáõîäèìîñòè âàêöèíàöèè Öèòàòà:
|
#60
|
||||
|
||||
Recommendations for Prevention and Control of Influenza in Children, 2011–2012
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |